The U.S. IPO market is expected to see a blowout 2025, fueled by the return of business-friendly Donald Trump to the White ...
The year 2025 is expected to see a resurgence of IPOs due to policy changes, monetary easing, and a favorable business ...
Shares of Ascentage Pharma Group International rose as much as 4% in the Chinese biopharmaceutical company’s US trading debut ...
After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 ...
In 2024, global and US markets saw a slight increase in IPOs. Syntax Data used its FIS classification system to analyze the ...
When Donald Trump’s real estate business wanted to break into the Indian market in 2012, it turned to Atul Chordia and his ...
The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics ...
U.S. liquefied natural gas exporter Venture Global couldn’t have timed its initial public offering better: It comes just days ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback